share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/09/24 21:21

Moomoo AI 已提取核心信息

BioVie announced a best efforts public offering of 1,960,800 shares of common stock and warrants at $1.53 per share on September 23, 2024. The offering includes common stock purchase warrants exercisable at $1.53 per share and pre-funded warrants at $1.5299 with a $0.0001 exercise price. ThinkEquity is acting as the sole placement agent.The company expects to raise approximately $3 million in gross proceeds before deducting placement agent fees and offering expenses. The offering is expected to close on September 25, 2024. The placement agent will receive warrants to purchase 98,040 shares at $1.9125 per share, representing 5% of the shares sold.The securities are being offered through the company's effective S-3 registration statement. BioVie intends to use the net proceeds primarily for working capital and general corporate purposes. The company develops innovative drug therapies for neurological disorders and advanced liver disease.
BioVie announced a best efforts public offering of 1,960,800 shares of common stock and warrants at $1.53 per share on September 23, 2024. The offering includes common stock purchase warrants exercisable at $1.53 per share and pre-funded warrants at $1.5299 with a $0.0001 exercise price. ThinkEquity is acting as the sole placement agent.The company expects to raise approximately $3 million in gross proceeds before deducting placement agent fees and offering expenses. The offering is expected to close on September 25, 2024. The placement agent will receive warrants to purchase 98,040 shares at $1.9125 per share, representing 5% of the shares sold.The securities are being offered through the company's effective S-3 registration statement. BioVie intends to use the net proceeds primarily for working capital and general corporate purposes. The company develops innovative drug therapies for neurological disorders and advanced liver disease.
BioVie公告计划于2024年9月23日以每股1.53美元公开发行1,960,800股普通股及Warrants。该发行包括每股1.53美元可行使的普通股购买Warrants和每股1.5299美元、执行价格为0.0001美元的预先资金Warrants。ThinkEquity担任唯一的配售代理。公司预计在扣除配售代理费用和发行费用之前，筹集约300万美金的毛收益。该发行预计于2024年9月25日完成。配售代理将获得以每股1.9125美元购买98,040股的Warrants，代表出售股票的5%。这些证券通过公司有效的S-3注册声明进行发行。BioVie计划将净收益主要用于营运资金和一般公司目的。该公司开发针对神经系统疾病和爱文思控股肝病的创新药物疗法。
BioVie公告计划于2024年9月23日以每股1.53美元公开发行1,960,800股普通股及Warrants。该发行包括每股1.53美元可行使的普通股购买Warrants和每股1.5299美元、执行价格为0.0001美元的预先资金Warrants。ThinkEquity担任唯一的配售代理。公司预计在扣除配售代理费用和发行费用之前，筹集约300万美金的毛收益。该发行预计于2024年9月25日完成。配售代理将获得以每股1.9125美元购买98,040股的Warrants，代表出售股票的5%。这些证券通过公司有效的S-3注册声明进行发行。BioVie计划将净收益主要用于营运资金和一般公司目的。该公司开发针对神经系统疾病和爱文思控股肝病的创新药物疗法。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    TuHURA Biosciences
    HURA
    -- 3.850
    Aditxt
    ADTX
    -- 10.0300
    COSCIENS Biopharma
    CSCI
    -- 4.350
    Forte Biosciences
    FBRX
    -- 7.020
    Lyell Immunopharma
    LYEL
    -- 0.582
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！